- Home
- ABEO vs CRDF Comparison
ABEO vs CRDF Comparison
Compare ABEO & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABEO
- CRDF
- Stock Information
- Founded
- ABEO 1974
- CRDF 1999
- Country
- ABEO United States
- CRDF United States
- Employees
- ABEO N/A
- CRDF N/A
- Industry
- ABEO Biotechnology: Pharmaceutical Preparations
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ABEO Health Care
- CRDF Health Care
- Exchange
- ABEO Nasdaq
- CRDF Nasdaq
- Market Cap
- ABEO 256.9M
- CRDF 210.2M
- IPO Year
- ABEO 1980
- CRDF N/A
- Fundamental
- Price
- ABEO $5.57
- CRDF $3.51
- Analyst Decision
- ABEO Strong Buy
- CRDF Strong Buy
- Analyst Count
- ABEO 6
- CRDF 5
- Target Price
- ABEO $18.00
- CRDF $10.50
- AVG Volume (30 Days)
- ABEO 1.1M
- CRDF 1.4M
- Earning Date
- ABEO 08-11-2025
- CRDF 08-07-2025
- Dividend Yield
- ABEO N/A
- CRDF N/A
- EPS Growth
- ABEO N/A
- CRDF N/A
- EPS
- ABEO N/A
- CRDF N/A
- Revenue
- ABEO N/A
- CRDF $587,000.00
- Revenue This Year
- ABEO N/A
- CRDF N/A
- Revenue Next Year
- ABEO $323.51
- CRDF N/A
- P/E Ratio
- ABEO N/A
- CRDF N/A
- Revenue Growth
- ABEO N/A
- CRDF N/A
- 52 Week Low
- ABEO $3.93
- CRDF $2.01
- 52 Week High
- ABEO $7.32
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- ABEO 37.51
- CRDF 55.21
- Support Level
- ABEO $5.66
- CRDF $2.96
- Resistance Level
- ABEO $6.24
- CRDF $3.24
- Average True Range (ATR)
- ABEO 0.26
- CRDF 0.26
- MACD
- ABEO -0.08
- CRDF -0.05
- Stochastic Oscillator
- ABEO 8.08
- CRDF 38.73
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.